Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Actinium Pharmaceuticals, Inc. (Delaware) Common Stock
(NY:
ATNM
)
1.670
+0.140 (+9.15%)
Official Closing Price
Updated: 8:00 PM EDT, May 16, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Actinium Pharmaceuticals, Inc. (Delaware) Common Stock
< Previous
1
2
3
4
5
Next >
Actinium Pharmaceuticals (ATNM) Poised for Breakout as Analysts Project Significant Upside
May 09, 2024
Via
AB Newswire
Actinium Pharmaceuticals (NYSE: ATNM): A Prime Target in a Wave of Radiopharmaceutical Mergers and Acquisitions
May 08, 2024
Via
AB Newswire
ATNM Stock Earnings: Actinium Pharmaceuticals Beats EPS for Q1 2024
April 29, 2024
ATNM stock results show that Actinium Pharmaceuticals beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market
April 25, 2024
The radiopharmaceuticals space could be worth up to $25 billion, according to one estimate.
Via
Investor's Business Daily
Actinium Pharmaceuticals (ATNM) Leads Biotech Innovation Amid Economic Uncertainty
April 19, 2024
Via
AB Newswire
Topics
Economy
Exposures
Interest Rates
(ATNM) - Analyzing Actinium Pharmaceuticals's Short Interest
March 09, 2023
Via
Benzinga
Navigating Interest Rate Speculations and M&A Trends with a Spotlight on Actinium Pharmaceuticals (ATNM)
April 18, 2024
Via
AB Newswire
Topics
Economy
Exposures
Interest Rates
Actinium Pharmaceuticals (ATNM) Garners Attention with Clinical Successes and Strategic Market Moves Amid Growing Radiopharma Interest
April 17, 2024
Via
AB Newswire
Biotech on a Budget: 7 Stocks Under $10 With Huge Potential
April 15, 2024
With the medical care industry always liable for negative surprises, you might as well go for big upside with under-$10 biotech stocks.
Via
InvestorPlace
Revolutionizing Targeted Cancer Treatment and Radiotherapy Manufacturing: Actinium Pharmaceuticals (NYSE: ATNM) Trailblazing Journey
March 28, 2024
Via
AB Newswire
Actinium Pharmaceuticals (ATNM) Spearheading the Future of Oncology with Iomab-ACT’s Innovative Clinical Trial
March 27, 2024
Via
AB Newswire
Actinium Pharmaceuticals (ATNM): A Prime Buyout Candidate Amidst a Radiopharma Acquisition Wave
March 26, 2024
Via
AB Newswire
Topics
Intellectual Property
Exposures
Intellectual Property
Actinium Pharmaceuticals Inc (NYSE:ATNM) Surges on Analyst Upgrade Amidst Radiopharma Sector Momentum
March 22, 2024
Via
AB Newswire
Topics
Artificial Intelligence
Intellectual Property
Exposures
Artificial Intelligence
Intellectual Property
Actinium Pharmaceuticals Inc (ATNM) Targets Breakthrough in Cancer Therapy: Proprietary Production of Vital Isotope Sparks Industry Buzz and Share Surge
March 21, 2024
Via
AB Newswire
Topics
Intellectual Property
Exposures
Intellectual Property
Actinium Pharmaceuticals Inc. (ATNM) Leads Breakthroughs in Targeted Radiotherapy with Iomab-B and Strategic Production of Actinium-225
March 20, 2024
Via
AB Newswire
Topics
Intellectual Property
Exposures
Intellectual Property
High-Risk, High-Reward: Little-Known Biotech Stock ATNM Could Soar on Breakthrough Cancer Treatment
March 15, 2024
ATNM stock offers moonshot or crash-landing possibilities as Actinium Pharmaceuticals works relentlessly to advance life-changing treatments.
Via
InvestorPlace
Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) launches strategic initiative focused on the manufacture of the highly sought after medical isotope Actinium-225 (Ac-225)
March 14, 2024
Via
AB Newswire
Topics
Intellectual Property
Exposures
Intellectual Property
7 Biotech Penny Stocks on the Verge of Clinical Trial Victory
February 25, 2024
Biotech penny stocks represent one heckuva risk. However, if the stars align, you could be talking some serious money.
Via
InvestorPlace
12 Health Care Stocks Moving In Friday's After-Market Session
February 09, 2024
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2023
September 06, 2023
Via
Benzinga
Actinium Pharma – Pivotal Results From Key New Drug In The Fight Against Cancer
July 14, 2023
Sandesh Seth, CEO & Chairman of the Board of Actinium Pharmaceuticals (NASDAQ: ATNM), was recently a guest on Benzinga’s All-Access.
Via
Benzinga
Actinium Pharma Cratered 37% Over Two Days — Here's Why, According To CEO Sandesh Seth
February 24, 2023
Actinium CEO Sandesh Seth says the tumble this week had little to do with clinical data.
Via
Investor's Business Daily
Global Market for Acute Myeloid Leukemia Expected to Reach $3.2 Billion By 2029
February 22, 2023
EQNX::TICKER_START (NYSE:ATNM),(NASDAQ:AZN),(NYSE:BMY),(NYSE:AMAM),(NYSE:GSK) EQNX::TICKER_END
Via
FinancialNewsMedia
Actinium Announces Positive Full Data Results From the Pivotal Phase 3 SIERRA Trial in Patients with Active, Relapsed or Refractory Acute Myeloid Leukemia
February 22, 2023
– Iomab-B met the primary endpoint of durable Complete Remission (dCR) of 6-months following initial complete remission after BMT with high statistical significance (p-value of <0.0001), 22% of...
Via
FinancialNewsMedia
Benzinga's Top Ratings Upgrades, Downgrades For February 21, 2023
February 21, 2023
Via
Benzinga
What's Going On With Actinium Pharmaceuticals Stock?
February 21, 2023
Actinium Pharmaceuticals Inc (AMEX:ATNM) shares are trading higher Tuesday after the company announced full data results from the pivotal Phase 3 SIERRA trial in patients with active, relapsed or...
Via
Benzinga
Why Owlet Shares Are Trading Higher By Over 45%; Here Are 20 Stocks Moving Premarket
February 21, 2023
Gainers Troika Media Group Inc (NASDAQ: TRKA) shares rose 65.9% to $0.37 in pre-market trading after dropping 4% on Friday.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
February 21, 2023
It's time to start another day of trading with a breakdown of the biggest pre-market stock movers traders need to know about for Tuesday!
Via
InvestorPlace
Actinium Pharmaceuticals’ Shares Stay Bullish Ahead Of Expected Topline Phase 3 Data Release In Q4 ($ATNM)
December 12, 2022
Via
AB Newswire
Actinium Pharmaceuticals’ Shares Rally Ahead Of Topline Phase 3 Data Release; Update Expected By Year’s End ($ATNM)
December 08, 2022
Via
AB Newswire
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.